RADFORD, Va., June 14 /PRNewswire-FirstCall/ -- New River Pharmaceuticals Inc. (Nasdaq: NRPH - News) announced today that it anticipates that results will be presented from its three clinical abuse liability studies on NRP104, a compound being developed as a treatment for attention-deficit/hyperactivity disorder (ADHD).
